Gliptivil Combo (Metformin Hydrochloride, Vildagliptin)

Gliptivil Combo is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to lifestyle therapy.

• As monotherapy or in combination when metformin alone does not achieve target glycemic levels.
• Adjunct to diet and exercise to improve overall blood glucose control.
• Use in patients who require both hepatic glucose reduction and enhanced incretin effect.
• May be considered when a single‑pill regimen simplifies treatment adherence.
• Suitable for patients needing additional glucose‑lowering effect beyond metformin.

The safety profile of Gliptivil Combo reflects the known effects of its individual components, metformin and vildagliptin.

Common

• Nausea or upset stomach.
• Diarrhea or abdominal discomfort.
• Headache.
• Upper respiratory tract infection symptoms (e.g., nasopharyngitis).
• Mild hypoglycemia when combined with other glucose‑lowering agents.

Serious

• Lactic acidosis (rare, associated with metformin).
• Acute pancreatitis (possible with vildagliptin).
• Severe hypoglycemia, especially when used with sulfonylureas or insulin.
• Significant renal impairment leading to drug accumulation.

Before initiating Gliptivil Combo, clinicians should evaluate several clinical factors to minimize risk.

• Assess renal function; avoid or adjust in moderate to severe renal impairment.
• Review hepatic status, as liver disease may affect drug metabolism.
• Monitor for signs of heart failure, particularly in patients with existing cardiac conditions.
• Consider pregnancy and lactation status; safety data are limited.
• Use cautiously in elderly patients who may have reduced renal clearance.
• Advise patients to limit excessive alcohol intake, which can increase lactic acidosis risk.
• Regularly monitor blood glucose and HbA1c to gauge therapeutic response.

Gliptivil Combo may interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Co‑administration with other metformin‑containing products, which can increase the risk of lactic acidosis.
• Use of strong CYP2C9 inhibitors (e.g., fluconazole) that raise vildagliptin plasma levels.
• Iodinated contrast agents in patients with compromised renal function.

Use with caution

• Sulfonylureas or insulin, due to an increased risk of hypoglycemia.
• Diuretics that may affect renal clearance of metformin.
• Corticosteroids or other agents that raise blood glucose, potentially requiring dose adjustments.
• Medications that alter gastric pH, which could affect metformin absorption.